Relaxin to help people with cardio-metabolic disease
Relaxera’s goal is to develop synthetic human Relaxin-2 for the chronic treatment of the aging heart, Heart Failure with preserved Ejection Fraction (HFpEF), impaired glucose tolerance, and for organ protection in the field of transplant medicine.
NEWS AND EVENTS
Clinical Study “Relaxin-2 for Patients with chronic symptomatic Heart Failure”
Relaxera is designing a clinical phase II study demonstrating the beneficial and pleiotropic effects of relaxin-2 in patients with heart failure. Title of the study: Synthetic human relaxin-2 for patients with chronic symptomatic heart failure with preserved and mildly reduced ejection fraction (HFpEF, HFmrEF) and [...]
Relaxera and University of Pittsburgh announce research cooperation
As of December 2017, Relaxera and the group of Prof. Guy Salama (Heart and Vascular Institute of The University of Pittsburgh) entered into a research cooperation regarding the effects of relaxin in an animal model of HFpEF (“aged rat”). The focus of this research will, [...]
COOPERATIONS AND PROJECTS
HFpEF – Heart Failure with preserved Ejection Fraction
HFpEF represents a distinct sub-entity of heart failure. Like heart failure in general, HFpEF is characterized by the inability of the heart to provide, at normal filling pressures, an output adequate to meet the physiologically varying demands of the body (Paulus 2007, The Task Force 2008). …